Fidelity SPDR Advertisement
Home > Boards > Free Zone > User's Groups > Mohacsy's Safe Portfolio Member Forum

Orphan Drug Status doesn't assure FDA approval of

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
n4807g Member Profile
Member Level 
Followed By 32
Posts 27,347
Boards Moderated 0
Alias Born 07/08/03
160x600 placeholder
Stocks End Mixed; OPEC Sinks Energy Sector
U.S. stocks posted a mixed finish in a holiday-shortened session Friday as energy shares got slammed a day after the Organization of the Petroleum Exporting Countries did nothing to alleviate a global supply glut.
Top Equities Stories Of The Day
How to X-Ray Your Portfolio
Canada Resident Caught Up in China Corruption Probe
Hutchison Whampoa Prepping Bid for U.K.'s EE or O2 -Reuters
Correction to La Compagnie Fares Story
London Oil Stocks Extend Losses On OPEC Target Decision
SEC Grants Bank of America Short-Term Waiver from Hedge-Fund Restrictions
Samsung to Buy Back $2 Billion Worth of Shares -- Update
European Oil Stocks Finish Lower After OPEC Holds Production Target
n4807g Member Level  Monday, 04/23/12 12:16:00 PM
Re: FullBoogie post# 60301
Post # of 68891 
Orphan Drug Status doesn't assure FDA approval of the compound being evaluated, it confers certain marketing advantages and tax credits should the drug be approved.

Like most small biotechs CYTR will succeed or fail on the technology they employ. In CYTR's case the delivery system. The near term future of INNO-206 will be clear when they report interim findings of their ongoing 2b trial.

Like all biotechs this is a speculative investment, but I've watched many companies with similar strategies do well. The preliminary data look promising (no guarantee) but as I said in my previous post Abraxane uses Albumin as the entry vehicle in tumors and CYTR uses the same concept.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist